Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Companies announce agreement to develop new drug targeting osteoporosis
September 8th, 2005
U.S. biotechnology company Velcura Therapeutics, Inc. announced a license agreement with Nippon Chemiphar Co. (Chemiphar), Ltd., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange. The license agreement enables the two companies to further develop new small molecule therapies for osteoporosis and other bone diseases. Osteoporosis is second only to cardiovascular disease as a world health problem, according to the World Health Organization. The two companies also announced that they have discovered their first lead compound and shown it to be very effective in animal models of osteoporosis. In 2006, Velcura Therapeutics plans to...
Source: Women's Health Weekly (2005-09-08)
|
